{"id":690185,"date":"2022-09-29T08:05:05","date_gmt":"2022-09-29T12:05:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/"},"modified":"2022-09-29T08:05:05","modified_gmt":"2022-09-29T12:05:05","slug":"crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/","title":{"rendered":"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy"},"content":{"rendered":"
\n

ZUG, Switzerland and BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in<\/p>\n

the BMO Biopharma Spotlight Series: Gene Editing and Therapy on Thursday, October 6, 2022, at 9:00 a.m. ET.<\/p>\n

A live webcast of the events will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https:\/\/crisprtx.gcs-web.com\/events<\/a>. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.<\/p>\n

\n About CRISPR Therapeutics<\/strong>\n <\/p>\n

CRISPR Therapeutics\u00a0is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR\/Cas9 platform. CRISPR\/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA.\u00a0CRISPR Therapeutics\u00a0has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts,\u00a0CRISPR Therapeutics\u00a0has established strategic partnerships with leading companies including\u00a0Bayer, Vertex Pharmaceuticals\u00a0and\u00a0ViaCyte, Inc.\u00a0CRISPR Therapeutics AG\u00a0is headquartered in\u00a0Zug, Switzerland, with its wholly-owned\u00a0U.S.\u00a0subsidiary,\u00a0CRISPR Therapeutics, Inc., and R&D operations based in\u00a0Boston, Massachusetts, and business offices in\u00a0San Francisco, California\u00a0and\u00a0London, United Kingdom. For more information, please visit\u00a0www.crisprtx.com<\/a>.<\/p>\n

CRISPR THERAPEUTICS\u00ae<\/sup> word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.<\/p>\n

\n Investor Contact:<\/strong>
\n
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com<\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ZUG, Switzerland and BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the BMO Biopharma Spotlight Series: Gene Editing and Therapy on Thursday, October 6, 2022, at 9:00 a.m. ET. A live webcast of the events will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https:\/\/crisprtx.gcs-web.com\/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation. About CRISPR Therapeutics CRISPR Therapeutics\u00a0is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases … <\/p>\n

Continue reading “CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690185","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland and BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the BMO Biopharma Spotlight Series: Gene Editing and Therapy on Thursday, October 6, 2022, at 9:00 a.m. ET. A live webcast of the events will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https:\/\/crisprtx.gcs-web.com\/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation. About CRISPR Therapeutics CRISPR Therapeutics\u00a0is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases … Continue reading "CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T12:05:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy\",\"datePublished\":\"2022-09-29T12:05:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/\"},\"wordCount\":299,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/\",\"name\":\"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE=\",\"datePublished\":\"2022-09-29T12:05:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/","og_locale":"en_US","og_type":"article","og_title":"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy - Market Newsdesk","og_description":"ZUG, Switzerland and BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the BMO Biopharma Spotlight Series: Gene Editing and Therapy on Thursday, October 6, 2022, at 9:00 a.m. ET. A live webcast of the events will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https:\/\/crisprtx.gcs-web.com\/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation. About CRISPR Therapeutics CRISPR Therapeutics\u00a0is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases … Continue reading \"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-29T12:05:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy","datePublished":"2022-09-29T12:05:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/"},"wordCount":299,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/","name":"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE=","datePublished":"2022-09-29T12:05:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTQyOSM1MTc3NjMwIzIwNDk5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690185"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690185\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}